Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The effects of denosumab compared with oral bisphosphonates (BP) in patients with RA complicated with osteoporosis on the progression of structural damage, BMD and disease activity.

Trial Profile

The effects of denosumab compared with oral bisphosphonates (BP) in patients with RA complicated with osteoporosis on the progression of structural damage, BMD and disease activity.

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Denosumab (Primary) ; Bisphosphonates
  • Indications Osteoporosis; Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms Two Birds

Most Recent Events

  • 03 Aug 2016 Status changed from recruiting to discontinued.
  • 17 Aug 2015 Planned End Date is 31 Mar 2017, according to University Hospital Medical Information Network - Japan record.
  • 08 Aug 2014 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top